ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Adenocarcinoma
Hypersensitivity
Recurrence
Breast Cancer

Prostate Cancer trials near Milano, Lombardia, ITA:

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (RAPSON)

prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)Open-label, randomized phase II trial in ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: Radium-223
Drug: Docetaxel

Phase 2

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Milano, Italy and 14 other locations

and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: abiraterone acetate
Drug: olaparib

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 131 other locations

Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: 177Lu-PSMA-I&T
Drug: Abiraterone with Prednisone or Enzalutamide

Phase 3

Curium

Milan, Italy and 51 other locations

second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate...

Enrolling
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Drug: PF-06821497
Drug: Enzalutamide

Phase 3

Pfizer
Pfizer

Milano, Italy and 159 other locations

pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate...

Enrolling
Metastatic Prostate Cancer
Drug: AZD5305
Drug: Enzalutamide

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Milano, Italy and 26 other locations

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutam...

Enrolling
Prostate Cancer
Drug: prednisone
Drug: enzalutamide

Phase 2

Astellas
Astellas

Cremona, Italy and 235 other locations

of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have...

Enrolling
Prostate Cancer Metastatic
Drug: Androgen deprivation therapy
Drug: Darolutamide 300 mg

Phase 3

Unicancer
Unicancer

Milano, Italy and 89 other locations

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alon...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: PF-06821497
Drug: Placebo

Phase 3

Pfizer
Pfizer

Milano, Italy and 154 other locations

compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: Docetaxel
Drug: Abiraterone

Phase 3

Celgene
Celgene

Milan, Lombardia, Italy and 237 other locations

At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and pat...

Active, not recruiting
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Procedure: Radiotherapy
Drug: androgen deprivation therapy (ADT)
Istituto Clinico Humanitas

Rozzano, Lombardia, Italy

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems